SEC Tracker
Get the app
REPL · XBRL financial data

Replimune Group financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (REPL's year ends in late March)

In millions of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Research and development4343*43434854*58585352*4934
Selling, general and administrative—————year only3326—year only1922
General and administrative1416*14151825*332619———
Total operating expenses5759*57596679*90847273*6856
Operating income (loss)(57)(59)*(57)(59)(66)(79)*(90)(84)(72)(73)*(68)(56)
Interest expense11*1111*1112*33
Other income (expense)1(1)*02(3)1*1(1)(1)(0)*(1)0
Income tax expense (benefit)0(0)*001(0)*00(0)(0)*——
Net income (loss)(51)(55)*(54)(53)(66)(74)*(87)(83)(71)(73)*(70)(57)
Earnings per share, basic USD per share(0.77)(0.83)*(0.78)(0.68)(0.79)(0.81)*(0.95)(0.90)(0.77)(0.77)*(0.72)(0.54)
Earnings per share, diluted USD per share(0.77)(0.83)*(0.78)(0.68)(0.79)(0.81)*(0.95)(0.90)(0.77)(0.77)*(0.72)(0.54)
Weighted average shares, basic millions of shares6767*69798391*92929296*97105
Weighted average shares, diluted millions of shares6767*69798391*92929296*97105

Balance sheet

CSV

Fiscal quarters (REPL's year ends in late March)

In millions of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Cash and cash equivalents987415211317211197102123209185308
Short-term investments36934631731936437330622114660100
Inventory—————————0—10
Prepaid and other current assets986988888956
Total current assets479434480443548496413334280279201324
Property and equipment, net91011131414151514131211
Right-of-use asset554444443333
Total assets533488535498604551470389334332252374
Accounts payable43187121566746
Total current liabilities394036444862605350583846
Long-term debt—45454646464747488384100
Lease liability, non-current444433333222
Total liabilities111113109117121135133126123166147169
Accumulated deficit(646)(701)(755)(808)(874)(949)(1,035)(1,118)(1,189)(1,263)(1,332)(1,389)
Total stockholders' equity422375426381482416337263211166106205
Total liabilities and equity533488535498604551470389334332252374
Common shares outstanding (cover page) millions of shares616168687777787883849495

Cash flows

CSV

Fiscal quarters (REPL's year ends in late March)

In millions of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Net income (loss)(51)(55)*(54)(53)(66)(74)*(87)(83)(71)(73)*(70)(57)
Stock-based compensation8*8*99*9*8*98*7*8*811*
Depreciation and amortization11*1111*1111*11
Net cash from operating activities(47)*(46)*(49)(39)*(51)*(54)*(77)(81)*(66)*(56)*(76)(48)*
Net cash from investing activities54*23*300*(46)*(8)*6584*75*87*5010*
Proceeds from issuing common stock0*0*480*108*(0)*00*————
Proceeds from long-term debt—0*———0*———year only——
Net cash from financing activities15*(0)*97(0)*156*(0)*(0)0*10*56*1161*
Net change in cash22*(23)*77(38)*59*(61)*(14)5*21*86*(24)122*

Compare with peers

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Replimune Group308not reported(48)*94.8M5.0 quarters 10-QSep 30, 2026
Heron Therapeutics21not reported(2.2)*189.9M19.3 quarters 10-QJun 30, 2026
Aldeyra Therapeutics45not reported(4.6)*60.3M9.8 quarters 10-QJun 30, 2026
Sagimet Biosciences166not reported(11)*not reported21.6 quarters 10-QJun 30, 2026
Annexon199not reported(48)*not reported4.4 quarters 10-QJun 30, 2026
Lifecore Biomedical23256.9*37.9M— 10-QSep 30, 2026
Precigen157412*358.5M— 10-QSep 30, 2026
DBV Technologies1661.6(52)*314.4M3.2 quarters 10-QSep 30, 2026
SELLAS Life Sciences Group138not reported(7.6)*201.9M18.2 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.